Evidence map›Paper›PMID 27617315›Full record

ArticleInvestigative and clinical urology2016

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.

Peter Ka-Fung Chiu, Jeremy Yuen-Chun Teoh, Wai-Man Lee, Chi-Hang Yee, Eddie Shu-Yin Chan, See-Ming Hou, Chi-Fai Ng

5 registry-linked trialsAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative and clinical urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03891732 active not recruitingnot on this mapstarted 2019, after this paper: background citation

The Use of MRI Prostate in Improving Detection of Significant Prostate Cancer in a Screening Population of Chinese Men With Elevated PSA

TypeobservationalSponsorChinese University of Hong KongRan2019 to 2024Enrolled690ConditionsProstate Cancer, PSA, MRIArmsMRI prostate
NCT04685928 nacompletednot on this mapstarted 2021, after this paper: background citation

A Randomized Controlled Trial Comparing Magnetic Resonance Imaging (MRI)-Targeted Biopsy and Extended Transperineal Systematic Biopsy for Detection of Clinically Significant Prostate Cancer: the SMART Trial

TypeinterventionalSponsorChinese University of Hong KongRan2021 to 2024Enrolled403ConditionsProstate CancerArmsMRI and MRI-guided prostate biopsy, TP-arm Systematic biopsy
NCT05438524 completednot on this mapstarted 2021, after this paper: background citation

The Performance of MRI Prostate in Men With Different Prostate Health Index (Phi) Values: Can we Save Some MRI Scans?

TypeobservationalSponsorChinese University of Hong KongRan2021 to 2024Enrolled159ConditionsProstate Cancer
NCT05443412 recruitingnot on this mapstarted 2023, after this paper: background citation

Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection: A Synergy of Novel Biomarkers, Advanced Imaging, and Robotic-assisted Diagnosis

TypeobservationalSponsorChinese University of Hong KongRan2023 to 2026Enrolled510ConditionsProstate CancerArmsDiagnostic test for prostate cancer
NCT07386496 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI: a Multi-center Randomised Controlled Trial

TypeinterventionalSponsorChinese University of Hong KongRan2026 to 2028Enrolled250ConditionsProstate CancerArmsMRI+PSMA-guided approach, MRI-guided approach
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peter Ka-Fung ChiuDepartment of Surgery, Division of Urology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Jeremy Yuen-Chun TeohDepartment of Surgery, Division of Urology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wai-Man LeeDepartment of Surgery, Division of Urology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Chi-Hang YeeDepartment of Surgery, Division of Urology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Eddie Shu-Yin ChanDepartment of Surgery, Division of Urology, The Chinese University of Hong Kong, Hong Kong SAR, China.
See-Ming HouDepartment of Surgery, Division of Urology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Chi-Fai NgDepartment of Surgery, Division of Urology, The Chinese University of Hong Kong, Hong Kong SAR, China.; Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated the extended use of Prostate Health Index (PHI) and percentage of [-2]pro-prostate-specific antigen (%p2PSA) in Chinese men with prostate-specific antigen (PSA) 10-20 ng/mL and normal digital rectal examination (DRE). MATERIALS AND

methodsAll consecutive Chinese men with PSA 10-20 ng/mL and normal DRE who agreed for transrectal ultrasound (TRUS)-guided 10-core prostate biopsy were recruited. Blood samples were taken immediately before TRUS-guided prostate biopsy. The performances of total PSA (tPSA), %free-to-total PSA (%fPSA), %p2PSA, and PHI were compared using logistic regression, receiver operating characteristic, and decision curve analyses (DCA).

resultsFrom 2008 to 2015, 312 consecutive Chinese men were included. Among them, 53 out of 312 (17.0%) men were diagnosed to have prostate cancer on biopsy. The proportions of men with positive biopsies were 6.7% in PHI<35, 22.8% in PHI 35-55, and 54.5% in PHI>55 (chi-square test, p<0.001). The area under curves (AUC) of the base model including age, tPSA and status of initial/repeated biopsy was 0.64. Adding %p2PSA and PHI to the base model improved the AUC to 0.79 (p<0.001) and 0.78 (p<0.001), respectively, and provided net clinical benefit in DCA. The positive biopsy rates of Gleason 7 or above prostate cancers were 2.2% for PHI<35, 7.9% for PHI 35-55, and 36.4% for PHI>55 (chi-square test, p<0.001). By utilizing the PHI cutoff of 35 to men with PSA 10-20 ng/mL and normal DRE, 57.1% (178 of 312) biopsies could be avoided.

conclusionsBoth PHI and %p2PSA performed well in predicting prostate cancer and high grade prostate cancer. The use of PHI and %p2PSA should be extended to Chinese men with PSA 10-20 ng/mL and normal DRE.

Indexed as

Digital Rectal ExaminationAgedAged, 80 and overBiopsy, Large-Core NeedleHumansMaleMiddle AgedPredictive Value of TestsProspective StudiesProstate-Specific AntigenProstatic NeoplasmsProtein PrecursorsROC CurveUltrasonography, Interventional(-2)pro-prostate-specific antigen, humanProstate-Specific AntigenProtein PrecursorsBiomarkersBiopsyProstateProstate neoplasmsProstate-specific antigen

Identifiers

PMID27617315
PMCPMC5017555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.